{"denomUnitsSelected":"Participants","description":"QOL will be measured using the QLQ-MY20, a patient-reported questionnaire about patient ability to function, symptoms related to the cancer and its treatment, overall health and quality of life, and perceived financial impact of the cancer and its treatment. Changes in raw score from baseline to end of treatment will be assessed, in each of the physical and mental health domains. The Wilcoxon signed-rank test will be utilized to assess changes in raw scores. Mean change, along with standard deviation will be reported.","reportingStatus":"NOT_POSTED","timeFrame":"Baseline up to progression, withdrawal, or end of treatment, assessed up to 5 years","title":"Change in EORTC QLQ-MY20 Scores From Baseline to End of Treatment","type":"OTHER_PRE_SPECIFIED"}